12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga · 03/06 12:05
Gainers
- Omada Health (NASDAQ:OMDA) shares rose 16.2% to $15.8 during Friday's pre-market session. The company's market cap stands at $787.5 million. The company's, Q4 earnings came out yesterday.
- Cue Biopharma (NASDAQ:CUE) stock increased by 10.18% to $0.32. The market value of their outstanding shares is at $26.2 million.
- BiomX (AMEX:PHGE) shares moved upwards by 9.56% to $6.3. The market value of their outstanding shares is at $9.1 million.
- Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 8.35% to $4.41. The company's market cap stands at $5.5 million.
- BNB Plus (NASDAQ:BNBX) stock rose 7.47% to $0.79. The market value of their outstanding shares is at $4.0 million.
- Tectonic Therapeutic (NASDAQ:TECX) shares rose 7.46% to $29.93. The market value of their outstanding shares is at $521.2 million.
Losers
- Calidi Biotherapeutics (AMEX:CLDI) shares fell 31.1% to $0.53 during Friday's pre-market session. The market value of their outstanding shares is at $5.5 million.
- Nutex Health (NASDAQ:NUTX) stock declined by 27.86% to $76.0. The market value of their outstanding shares is at $744.9 million. The company's, Q4 earnings came out yesterday.
- Owlet (NYSE:OWLT) shares fell 21.79% to $9.19. The company's market cap stands at $324.0 million. As per the press release, Q4 earnings came out yesterday.
- Psyence Biomedical (NASDAQ:PBM) stock decreased by 21.49% to $2.01. The market value of their outstanding shares is at $2.6 million.
- Impact BioMedical (AMEX:IBO) stock decreased by 12.86% to $0.56. The market value of their outstanding shares is at $7.8 million.
- GridAI Technologies (NASDAQ:GRDX) shares fell 8.56% to $2.03. The market value of their outstanding shares is at $7.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.